Cencora, Inc. reported strong results for its fiscal year 2025 first quarter ended December 31, 2024. Revenue increased 12.8% year-over-year to $81.5 billion. Adjusted diluted EPS rose 13.7% to $3.73 in the fiscal first quarter, compared to $3.28 in the prior year.
The U.S. Healthcare Solutions segment continued its strong performance, with revenue increasing 13.6% to $74.0 billion and operating income up 9.9% to $767.3 million. The International Healthcare Solutions segment saw revenue increase 5.5% to $7.5 billion, though operating income decreased 2.9% to $182.1 million.
Cencora updated its fiscal year 2025 adjusted diluted EPS guidance, raising it to a range of $15.25 to $15.55, up from the previous range of $15.15 to $15.45. The company also declared a quarterly cash dividend of $0.55 per common share, payable March 3, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.